secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fusion Pharmaceuticals Inc. (—)
CIK:        0001805890
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-070701
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AstraZeneca to acquire Fusion Pharmaceuticals for $21 cash + $3 CVR per share
-----------------------------------------------------------------------------

- Per share consideration: $21.00 cash plus contingent value right (CVR) for up to $3.00 cash upon FDA acceptance of NDA for FPI-2265 in mCRPC by Aug 31, 2029.
- Termination fee: Fusion pays $71.68M to AstraZeneca if it accepts superior proposal; AstraZeneca pays $102.4M to Fusion if antitrust conditions not met.
- Supporting shareholders (~31% of outstanding shares) entered into voting and support agreements to vote in favor of the arrangement.
- Arrangement requires 66⅔% shareholder approval, court approval, and regulatory clearances under U.S. HSR and Canadian Competition Act.
- Expected close by September 18, 2024; special meeting of shareholders to be held.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1805890/000119312524070701/0001193125-24-070701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1805890/000119312524070701/d739068d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-070701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer